,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABLIM3,KIAA0843,ENSG00000173210,Actin binding LIM protein family member 3,5,149141483-149260542,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003245,Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,Renal cancer:1.28e-4 (unfavourable),Mixed,Tissue enhanced,,parathyroid gland: 79.4,adipose tissue: 63.7,Cell line enhanced,,TIME: 84.5
1,ADAMTS3,"ADAMTS-4, KIAA0366",ENSG00000156140,ADAM metallopeptidase with thrombospondin type 1 motif 3,4,72280969-72569386,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"HPA021368, HPA021369",Uncertain,,Approved,Intermediate filaments,,Mixed,Tissue enhanced,,parathyroid gland: 7.3,testis: 3.5,Cell line enhanced,,AF22: 13.0;HEL: 12.6;K-562: 10.9;U-2 OS: 8.7
2,ADGRL3,"KIAA0768, LEC3, LPHN3",ENSG00000150471,Adhesion G protein-coupled receptor L3,4,61201258-62078335,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA015027, HPA015762, CAB022698",Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 42.0;parathyroid gland: 30.6,"cervix, uterine: 8.5",Cell line enhanced,,AF22: 41.2;EFO-21: 10.2
3,ALCAM,"CD166, MEMD",ENSG00000170017,Activated leukocyte cell adhesion molecule,3,105366909-105576900,"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002148, HPA010926",Approved,,,,Renal cancer:3.15e-4 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 471.5,lung: 111.2,Cell line enhanced,,U-138 MG: 467.1
4,ALPK3,"KIAA1330, MAK, Midori",ENSG00000136383,Alpha kinase 3,15,84816680-84873482,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026558,Uncertain,,Approved,Nucleus,Renal cancer:3.95e-7 (favourable),Mixed,Tissue enhanced,,heart muscle: 32.8;parathyroid gland: 36.2;skeletal muscle: 47.6,adipose tissue: 12.3,Cell line enhanced,,BEWO: 12.8;HUVEC TERT2: 12.1;LHCN-M2: 16.5;NTERA-2: 12.1;RH-30: 34.1
5,AMPD3,,ENSG00000133805,Adenosine monophosphate deaminase 3,11,10308313-10507579,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038662, HPA047408",Uncertain,,Enhanced,Nuclear membrane,Endometrial cancer:2.37e-4 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 54.4,bone marrow: 41.4,Cell line enhanced,,BJ hTERT+: 35.8
6,ANKRD45,"CT117, FLJ45235",ENSG00000183831,Ankyrin repeat domain 45,1,173609561-173669862,Predicted intracellular proteins,Evidence at protein level,"HPA031655, HPA031656, HPA031657",Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 35.0;parathyroid gland: 22.9;testis: 36.3,cerebral cortex: 7.2,Cell line enhanced,,AF22: 9.4;BJ hTERT+ SV40 Large T+ RasG12V: 5.0;SH-SY5Y: 9.1
7,ANO5,"GDD1, LGMD2L, TMEM16E",ENSG00000171714,Anoctamin 5,11,22193176-22283357,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA058857,Uncertain,,,,Renal cancer:2.50e-7 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 56.1,skeletal muscle: 23.6,Cell line enhanced,,A549: 4.5;HAP1: 5.6;HEK93: 6.2
8,ARFGEF3,"BIG3, C6orf92, dJ171N11.1, KIAA1244, PPP1R33",ENSG00000112379,ARFGEF family member 3,6,138161921-138344663,Predicted intracellular proteins,Evidence at protein level,HPA036350,Uncertain,,,,Breast cancer:8.20e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 23.7;parathyroid gland: 29.7,prostate: 19.2,Cell line enhanced,,RH-30: 13.0;RT4: 15.4;SK-BR-3: 16.6
9,ARG2,,ENSG00000081181,Arginase 2,14,67619798-67651720,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000663, CAB009435",Enhanced,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,parathyroid gland: 94.0;prostate: 161.0;thyroid gland: 157.2,kidney: 63.4,Cell line enhanced,,HAP1: 54.8
10,ARHGAP44,"KIAA0672, RICH-2, RICH2",ENSG00000006740,Rho GTPase activating protein 44,17,12789539-12991643,Predicted intracellular proteins,Evidence at protein level,HPA038814,Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 51.6,cerebral cortex: 33.4,Cell line enhanced,,HEK93: 9.0
11,ARSK,"DKFZp313G1735, TSULF",ENSG00000164291,Arylsulfatase family member K,5,95555074-95605064,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA042384,Approved,,Approved,Nucleus<br>Vesicles,Liver cancer:2.59e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 22.7,thyroid gland: 8.5,Expressed in all,,
12,ARTN,"ENOVIN, EVN, NBN",ENSG00000117407,Artemin,1,43933320-43937241,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Ovarian cancer:8.18e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 21.2,seminal vesicle: 12.2,Cell line enhanced,,A-431: 60.4;HaCaT: 62.8;HBEC3-KT: 45.5
13,ATP13A4,"DKFZp761I1011, FLJ37958",ENSG00000127249,ATPase 13A4,3,193402077-193593111,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA051932,,,Approved,Nucleoplasm,Head and neck cancer:3.91e-4 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 87.9;parathyroid gland: 131.5;thyroid gland: 68.5,lung: 53.7,Cell line enriched,7.0,SCLC-21H: 4.6
14,ATP8A1,ATPIA,ENSG00000124406,ATPase phospholipid transporting 8A1,4,42408373-42657105,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA052935,Enhanced,,Supported,Vesicles,Renal cancer:5.54e-10 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 68.8;thyroid gland: 66.6,cerebral cortex: 58.2,Cell line enhanced,,AN3-CA: 25.5;Daudi: 33.1
15,B3GNT9,MGC4655,ENSG00000237172,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9",16,67148105-67151214,Predicted secreted proteins,Evidence at protein level,"HPA052743, HPA062734",Approved,,Supported,Nucleoli fibrillar center<br>Golgi apparatus,,Expressed in all,Tissue enhanced,,parathyroid gland: 49.9,thyroid gland: 28.2,Cell line enhanced,,SiHa: 49.7
16,BPIFB4,"C20orf186, dJ726C3.5, LPLUNC4",ENSG00000186191,BPI fold containing family B member 4,20,33079644-33111751,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,parathyroid gland: 1.3,testis: 0.7,Cell line enhanced,,HSkMC: 1.7;U-2 OS: 4.0
17,BTBD11,"ABTB2B, FLJ33957",ENSG00000151136,BTB domain containing 11,12,107318413-107659642,Predicted intracellular proteins,Evidence at protein level,HPA055898,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,parathyroid gland: 130.5,thyroid gland: 31.7,Cell line enhanced,,A549: 22.8;MOLT-4: 14.0
18,C1orf112,FLJ10706,ENSG00000000460,Chromosome 1 open reading frame 112,1,169662007-169854080,Predicted intracellular proteins,Evidence at protein level,"HPA023778, HPA024451",Uncertain,,Approved,Mitochondria,Endometrial cancer:9.56e-5 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 25.0,testis: 18.6,Expressed in all,,
19,C8orf34,"vest-1, VEST1",ENSG00000165084,Chromosome 8 open reading frame 34,8,68330722-68819022,Predicted intracellular proteins,Evidence at protein level,"HPA044420, HPA053065",Uncertain,,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus,,Mixed,Tissue enhanced,,fallopian tube: 14.7;parathyroid gland: 18.7,cerebral cortex: 6.1,Cell line enhanced,,HEK93: 2.4;LHCN-M2: 1.9;RH-30: 2.3
20,CABLES1,"FLJ35924, HsT2563",ENSG00000134508,Cdk5 and Abl enzyme substrate 1,18,23134564-23260467,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA073649,,,Supported,Nucleus<br>Nuclear bodies,Renal cancer:4.71e-6 (favourable),Tissue enriched,Tissue enhanced,,parathyroid gland: 60.1,lung: 32.2,Cell line enhanced,,SK-MEL-30: 120.1;U-266/70: 164.7
21,CCDC148,MGC125588,ENSG00000153237,Coiled-coil domain containing 148,2,158171081-158456753,Predicted intracellular proteins,Evidence at protein level,HPA042626,Uncertain,,Approved,Nucleus<br>Nucleoli,Thyroid cancer:2.54e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 4.2;testis: 5.8,fallopian tube: 2.4,Cell line enhanced,,CAPAN-2: 2.2;HBF TERT88: 1.7;SCLC-21H: 2.0
22,CCDC151,MGC20983,ENSG00000198003,Coiled-coil domain containing 151,19,11420604-11435782,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA044184, HPA054626",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,fallopian tube: 13.4;parathyroid gland: 6.8;testis: 7.5,cerebral cortex: 2.0,Cell line enhanced,,SCLC-21H: 2.4;T-47d: 4.5
23,CCDC163,"C1orf231, CCDC163P, LOC126661",ENSG00000280670,Coiled-coil domain containing 163,1,45493866-45500079,Predicted membrane proteins,Evidence at transcript level,,,,,,Thyroid cancer:5.05e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 2.3,thyroid gland: 1.5,Cell line enhanced,,U-266/70: 5.1
24,CCDC181,"C1orf114, FLJ25846",ENSG00000117477,Coiled-coil domain containing 181,1,169394870-169460669,Predicted intracellular proteins,Evidence at protein level,"HPA027189, HPA027275, HPA027281, HPA027312",Enhanced,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,parathyroid gland: 22.9;testis: 49.6,fallopian tube: 19.6,Cell line enhanced,,NTERA-2: 13.8;SCLC-21H: 9.9;SH-SY5Y: 10.5
25,CCNA1,CT146,ENSG00000133101,Cyclin A1,13,36431520-36442882,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA060646,,,Approved,Nucleoplasm<br>Nuclear bodies,Head and neck cancer:1.70e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 59.6;testis: 144.6,fallopian tube: 27.9,Cell line enhanced,,HMC-1: 300.4;THP-1: 46.6;U-937: 68.5
26,CCND1,"BCL1, D11S287E, PRAD1, U21B31",ENSG00000110092,Cyclin D1,11,69641087-69654474,"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB000024, HPA027802",Uncertain,,Supported,Nucleoplasm,"Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 340.4,skin: 140.5,Cell line enhanced,,WM-115: 1198.2
27,CD4,,ENSG00000010610,CD4 molecule,12,6786858-6820808,"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000011, HPA004252, HPA004472, CAB068180",Enhanced,,Supported,Plasma membrane,"Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 549.0,spleen: 220.5,Group enriched,5.0,HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
28,CDH1,"CD324, UVO, uvomorulin",ENSG00000039068,Cadherin 1,16,68737225-68835548,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857",Enhanced,,Supported,Golgi apparatus<br>Plasma membrane<br>Cell Junctions,Renal cancer:2.06e-4 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 475.1,thyroid gland: 266.2,Cell line enhanced,,BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
29,CDH2,"CD325, CDHN, NCAD",ENSG00000170558,Cadherin 2,18,27950966-28177446,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000141, CAB018580, HPA058574, CAB078686",Enhanced,,Supported,Plasma membrane<br>Cell Junctions,,Expressed in all,Tissue enhanced,,heart muscle: 123.5;parathyroid gland: 126.2,adrenal gland: 87.3,Cell line enhanced,,AF22: 306.2;fHDF/TERT166: 367.9
30,CDH23,"CDHR23, DFNB12, USH1D",ENSG00000107736,Cadherin related 23,10,71396934-71815947,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017232,Approved,,,,Urothelial cancer:3.40e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 30.2,ovary: 19.4,Cell line enhanced,,RT4: 11.9;SCLC-21H: 6.6
31,CGN,KIAA1319,ENSG00000143375,Cingulin,1,151510510-151538692,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017193, HPA027586, HPA027587, HPA027657",Enhanced,,Supported,Plasma membrane<br>Cell Junctions,Renal cancer:5.84e-10 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 73.4,small intestine: 61.9,Cell line enhanced,,CACO-2: 75.4;CAPAN-2: 52.0
32,CHEK1,CHK1,ENSG00000149554,Checkpoint kinase 1,11,125625136-125676255,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044364,,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 62.5;seminal vesicle: 52.6,testis: 22.1,Expressed in all,,
33,CHRFAM7A,"CHRNA7-DR1, D-10",ENSG00000166664,CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion,15,30357766-30393849,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,parathyroid gland: 5.0;testis: 5.4,thyroid gland: 2.5,Cell line enhanced,,HAP1: 3.9;HEL: 3.3;RH-30: 2.7;SH-SY5Y: 3.8;U-937: 3.1
34,CHRNA4,"BFNC, EBN, EBN1",ENSG00000101204,Cholinergic receptor nicotinic alpha 4 subunit,20,63343223-63378401,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB034064,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.9;parathyroid gland: 17.4,liver: 3.9,Cell line enhanced,,U-2 OS: 2.6
35,CHST1,"C6ST, KSGal6ST",ENSG00000175264,Carbohydrate sulfotransferase 1,11,45648877-45665622,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:4.64e-7 (unfavourable), Liver cancer:3.95e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 49.0;parathyroid gland: 19.1,thyroid gland: 9.9,Cell line enhanced,,HUVEC TERT2: 11.4;TIME: 10.8;WM-115: 35.6
36,CISD1,"C10orf70, MDS029, mitoNEET, ZCD1",ENSG00000122873,CDGSH iron sulfur domain 1,10,58269058-58289586,Predicted membrane proteins,Evidence at protein level,HPA074383,,,Supported,Mitochondria,"Breast cancer:1.11e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable), Urothelial cancer:6.69e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 118.3,cerebral cortex: 27.2,Expressed in all,,
37,CLDN9,,ENSG00000213937,Claudin 9,16,3012456-3014505,Predicted membrane proteins,Evidence at protein level,HPA076613,,,Supported,Vesicles<br>Cell Junctions,"Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 3.2,bone marrow: 1.7,Cell line enhanced,,CAPAN-2: 5.5;MCF7: 16.8;SCLC-21H: 19.5
38,CNNM2,ACDP2,ENSG00000148842,Cyclin and CBS domain divalent metal cation transport mediator 2,10,102918293-103090221,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA059954, HPA071631",,,Enhanced,Vesicles,Renal cancer:2.39e-8 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 33.6,placenta: 12.4,Expressed in all,,
39,CNTN4,BIG-2,ENSG00000144619,Contactin 4,3,2098813-3057956,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.00e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 48.7,testis: 24.3,Group enriched,6.0,BEWO: 8.1;CACO-2: 7.6;HEK93: 5.1;SH-SY5Y: 18.0;WM-115: 5.6
40,COL26A1,"EMI6, EMID2, Emu2",ENSG00000160963,Collagen type XXVI alpha 1 chain,7,101362820-101559024,Predicted secreted proteins,Evidence at protein level,HPA027059,Approved,,Approved,Vesicles,Liver cancer:2.32e-5 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 10.2;parathyroid gland: 5.4,prostate: 3.1,Cell line enhanced,,AF22: 29.3;BEWO: 22.8;HAP1: 10.9;NTERA-2: 25.1
41,COL8A1,"C3orf7, MGC9568",ENSG00000144810,Collagen type VIII alpha 1 chain,3,99638475-99799226,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA053107,Enhanced,,Supported,Vesicles,Renal cancer:9.39e-8 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 87.4,lung: 56.9,Cell line enhanced,,fHDF/TERT166: 930.0;LHCN-M2: 289.1;TIME: 423.8
42,COL9A2,"EDM2, MED",ENSG00000049089,Collagen type IX alpha 2 chain,1,40300487-40317816,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA056316, HPA075286",Approved,,Approved,Nucleus<br>Vesicles,Endometrial cancer:5.13e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 53.4,seminal vesicle: 32.4,Cell line enhanced,,HDLM-2: 91.5;HMC-1: 79.4;THP-1: 69.5
43,COLQ,EAD,ENSG00000206561,Collagen like tail subunit of asymmetric acetylcholinesterase,3,15450133-15521751,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA045876,,,Approved,Plasma membrane<br>Cell Junctions,,Mixed,Tissue enhanced,,parathyroid gland: 19.4,fallopian tube: 17.6,Cell line enhanced,,BEWO: 13.9;HDLM-2: 4.5;U-937: 5.9
44,CYP4V2,CYP4AH1,ENSG00000145476,Cytochrome P450 family 4 subfamily V member 2,4,186191520-186213456,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA029122,Approved,,Approved,Nuclear speckles,"Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 65.1,liver: 47.4,Cell line enhanced,,SK-MEL-30: 19.3
45,CYP7B1,SPG5A,ENSG00000172817,Cytochrome P450 family 7 subfamily B member 1,8,64587763-64798761,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA017761,Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 40.3,thyroid gland: 22.4,Cell line enhanced,,HSkMC: 11.3;SH-SY5Y: 6.2;WM-115: 11.7
46,DDO,,ENSG00000203797,D-aspartate oxidase,6,110391771-110415562,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA037525, HPA037526",Enhanced,,Supported,Cytosol,Renal cancer:8.69e-5 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 24.3,heart muscle: 12.2,Cell line enhanced,,RPMI-8226: 10.9;U-937: 13.6
47,DIRC3,FLJ14199,ENSG00000231672,Disrupted in renal carcinoma 3,2,217284019-217756593,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,parathyroid gland: 1.3,testis: 0.7,Not detected,,
48,DMRTA1,,ENSG00000176399,DMRT like family A1,9,22446841-22455740,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA044764, HPA062253",Uncertain,,Approved,Vesicles,Renal cancer:1.14e-6 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 6.5,liver: 4.3,Cell line enhanced,,BJ hTERT+: 5.1
49,DPP4,"ADCP2, CD26, DPPIV",ENSG00000197635,Dipeptidyl peptidase 4,2,161992241-162074542,"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB045970,Enhanced,,,,"Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 550.6,placenta: 169.1,Cell line enhanced,,ASC diff: 115.0;ASC TERT1: 118.1;BJ hTERT+: 131.1;RPTEC TERT1: 175.8
50,DSG2,CDHF5,ENSG00000046604,Desmoglein 2,18,31498043-31549008,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA004896, CAB025122",Enhanced,,Enhanced,Plasma membrane<br>Cell Junctions,"Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 251.3,rectum: 106.9,Cell line enhanced,,HaCaT: 233.0;hTERT-HME1: 159.3
51,EDA,"ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED",ENSG00000158813,Ectodysplasin A,X,69616067-70039469,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA037972, HPA037973",,,Supported,Vesicles<br>Lipid droplets,Renal cancer:1.04e-9 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 19.4,thyroid gland: 10.0,Cell line enhanced,,EFO-21: 5.0;Hep G2: 12.2
52,ELOVL2,Ssc2,ENSG00000197977,ELOVL fatty acid elongase 2,6,10980759-11044314,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Breast cancer:6.73e-5 (favourable),Group enriched,Tissue enhanced,,liver: 27.6;parathyroid gland: 36.7;placenta: 50.2,cerebral cortex: 22.8,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
53,EMX1,,ENSG00000135638,Empty spiracles homeobox 1,2,72916260-72936071,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA006230, HPA006421",Approved,,Approved,Nucleoli,Renal cancer:1.54e-6 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.3;kidney: 15.5;parathyroid gland: 5.0,testis: 2.6,Cell line enhanced,,BEWO: 2.2;CACO-2: 3.1;HEK93: 7.5
54,EN2,,ENSG00000164778,Engrailed homeobox 2,7,155458129-155464831,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA045646, HPA069809",,,Supported,Nucleus<br>Nucleoli fibrillar center,Glioma:2.82e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 2.0;testis: 1.1,endometrium: 0.6,Cell line enhanced,,AF22: 40.5;AN3-CA: 14.1;HEK93: 23.0
55,ENPP1,"M6S1, NPPS, PC-1, PCA1, PDNP1",ENSG00000197594,Ectonucleotide pyrophosphatase/phosphodiesterase 1,6,131808016-131895155,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB032904, HPA062066",Enhanced,,,,,Expressed in all,Tissue enhanced,,parathyroid gland: 54.3;placenta: 62.9,thyroid gland: 34.1,Cell line enhanced,,ASC diff: 23.4;U-138 MG: 27.3
56,EPOR,,ENSG00000187266,Erythropoietin receptor,19,11377205-11384342,"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA077613,,,Supported,Vesicles,Pancreatic cancer:3.17e-5 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 53.1,thyroid gland: 18.0,Mixed,,
57,ERMP1,"FLJ23309, FXNA, KIAA1815",ENSG00000099219,Endoplasmic reticulum metallopeptidase 1,9,5765076-5833117,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA020584,Uncertain,,Approved,Nucleus<br>Nucleoli,Renal cancer:5.83e-10 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 124.7,thyroid gland: 44.0,Cell line enhanced,,RT4: 122.7
58,ESRRG,NR3B3,ENSG00000196482,Estrogen related receptor gamma,1,216503246-217137755,"FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA044678,Uncertain,,Approved,Nucleus,Renal cancer:1.13e-11 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 77.5,kidney: 31.3,Group enriched,7.0,RPMI-8226: 16.0;SCLC-21H: 9.4;SH-SY5Y: 44.7
59,ETV4,"E1A-F, E1AF, PEA3",ENSG00000175832,ETS variant 4,17,43527844-43579620,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005768,Approved,,Supported,Nucleoli,"Liver cancer:2.48e-4 (unfavourable), Thyroid cancer:7.60e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 30.3,cerebral cortex: 13.6,Cell line enhanced,,AN3-CA: 164.6;SK-MEL-30: 152.6
60,ETV5,ERM,ENSG00000244405,ETS variant 5,3,186046308-186110318,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009590, HPA063065",Approved,,Supported,Nucleoplasm,Liver cancer:7.85e-9 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 114.5,cerebral cortex: 74.7,Cell line enhanced,,SK-MEL-30: 141.2
61,EXPH5,SLAC2-B,ENSG00000110723,Exophilin 5,11,108505431-108593738,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Endometrial cancer:3.42e-6 (favourable), Head and neck cancer:1.46e-4 (favourable), Renal cancer:2.43e-4 (favourable), Lung cancer:5.12e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 16.1;skin: 31.3,esophagus: 8.2,Cell line enhanced,,hTERT-HME1: 8.7;RT4: 16.3
62,EYA1,BOR,ENSG00000104313,EYA transcriptional coactivator and phosphatase 1,8,71197433-71362232,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA028917,,,Supported,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,parathyroid gland: 81.7;prostate: 21.2,cerebral cortex: 10.7,Cell line enhanced,,AN3-CA: 28.1;RH-30: 23.1;SH-SY5Y: 57.2
63,F8A3,,ENSG00000277150,Coagulation factor VIII-associated 3,X,155456914-155458672,Predicted intracellular proteins,Evidence at protein level,HPA046960,Uncertain,,,,,Not detected,Tissue enhanced,,parathyroid gland: 32.9,cerebral cortex: 10.5,Cell line enhanced,,U-266/70: 31.3;U-266/84: 28.7
64,FAM124B,FLJ22746,ENSG00000124019,Family with sequence similarity 124 member B,2,224378698-224402085,Predicted intracellular proteins,Evidence at protein level,HPA070240,Approved,,Approved,Nucleoplasm<br>Mitochondria,,Tissue enriched,Tissue enhanced,,parathyroid gland: 9.8;placenta: 12.5,"lung,smooth muscle: 3.6",Cell line enriched,7.0,HUVEC TERT2: 88.9
65,FAM189A1,"KIAA0574, TMEM228",ENSG00000104059,Family with sequence similarity 189 member A1,15,29120254-29570723,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA009410, HPA010637",Uncertain,,Supported,Nucleus,,Mixed,Tissue enhanced,,cerebral cortex: 2.2;parathyroid gland: 2.0,"colon,testis: 0.8",Cell line enhanced,,EFO-21: 4.4;HDLM-2: 11.1;REH: 2.6
66,FGF13,"FGF2, FHF2",ENSG00000129682,Fibroblast growth factor 13,X,138614731-139222777,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA002809,,,Supported,Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 108.4,cerebral cortex: 47.9,Cell line enhanced,,AF22: 42.4;HAP1: 40.9;U-2197: 64.4;WM-115: 37.0
67,FIBCD1,FLJ14810,ENSG00000130720,Fibrinogen C domain containing 1,9,130902438-130939286,Predicted intracellular proteins,Evidence at protein level,"HPA053898, HPA055353",Uncertain,,Supported,Cell Junctions,,Mixed,Tissue enhanced,,adrenal gland: 4.7;parathyroid gland: 8.6;testis: 5.3,cerebral cortex: 2.5,Cell line enhanced,,MCF7: 25.2;RPTEC TERT1: 18.5;U-2 OS: 17.4;U-251 MG: 11.7
68,FIGNL2,,ENSG00000261308,Fidgetin like 2,12,51817840-51848766,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,kidney: 2.3;parathyroid gland: 2.4,placenta: 1.1,Cell line enhanced,,AF22: 17.1;BEWO: 10.8;NTERA-2: 6.9
69,FOXL2,"BPES, BPES1",ENSG00000183770,Forkhead box L2,3,138944224-138947140,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA069613,Enhanced,,Supported,Nucleus<br>Cytokinetic bridge,,Mixed,Tissue enhanced,,endometrium: 12.1;ovary: 29.6;parathyroid gland: 24.4,fallopian tube: 7.7,Cell line enhanced,,A-431: 4.3;fHDF/TERT166: 4.3;HEL: 7.2;hTCEpi: 5.1;K-562: 7.5;SiHa: 5.9
70,FOXL2NB,"C3orf72, FLJ43329",ENSG00000206262,FOXL2 neighbor,3,138947234-138953451,Predicted intracellular proteins,Evidence at protein level,"HPA061017, HPA071790",,,Supported,Nucleoli fibrillar center,,Mixed,Tissue enhanced,,endometrium: 29.1;ovary: 50.7;parathyroid gland: 63.8,fallopian tube: 19.5,Cell line enhanced,,AN3-CA: 4.1;fHDF/TERT166: 6.7;HEL: 7.8;SiHa: 7.1
71,FSCN2,"RFSN, RP30",ENSG00000186765,"Fascin actin-bundling protein 2, retinal",17,81528396-81537130,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 4.3;thyroid gland: 2.9,"fallopian tube,stomach: 0.8",Cell line enhanced,,EFO-21: 1.8;T-47d: 1.9
72,GATA3,HDR,ENSG00000107485,GATA binding protein 3,10,8053604-8075198,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB016217, HPA029730",Enhanced,,Supported,Nucleoplasm,Renal cancer:3.13e-4 (unfavourable),Group enriched,Tissue enhanced,,parathyroid gland: 235.0;skin: 148.9,placenta: 44.3,Cell line enhanced,,BEWO: 172.2;MCF7: 354.3;RT4: 149.5;SH-SY5Y: 145.4;T-47d: 506.9
73,GCNT1,"C2GNT, NACGT2, NAGCT2",ENSG00000187210,"Glucosaminyl (N-acetyl) transferase 1, core 2",9,76419850-76507416,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA003522, HPA003523, HPA031151",Uncertain,,Supported,Nuclear speckles,"Urothelial cancer:4.96e-4 (unfavourable), Endometrial cancer:8.44e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 186.4,duodenum: 50.1,Cell line enhanced,,HHSteC: 38.9
74,GJA1,"CX43, GJAL, ODD, ODDD, ODOD, SDTY3",ENSG00000152661,Gap junction protein alpha 1,6,121435692-121449727,"Cancer-related genes, Disease related genes, Predicted membrane proteins",Evidence at protein level,"CAB010753, HPA035097, HPA047551, HPA069245",Enhanced,Supported,Supported,Nucleoplasm<br>Vesicles<br>Cell Junctions,Stomach cancer:4.99e-5 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 651.5,skin: 469.0,Cell line enhanced,,HUVEC TERT2: 306.6;NTERA-2: 370.8;U-87 MG: 348.4
75,GJA3,"CX46, CZP3",ENSG00000121743,Gap junction protein alpha 3,13,20138255-20161049,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA014821,Supported,,,,,Tissue enhanced,Tissue enhanced,,heart muscle: 5.1;parathyroid gland: 5.9;placenta: 3.5,testis: 2.4,Cell line enhanced,,CAPAN-2: 6.8;HL-60: 5.2
76,GLB1L2,,ENSG00000149328,Galactosidase beta 1 like 2,11,134331874-134378341,Predicted secreted proteins,Evidence at protein level,"HPA054808, HPA059955",Uncertain,,Supported,Nucleus,,Mixed,Tissue enhanced,,parathyroid gland: 53.2;prostate: 56.1,fallopian tube: 41.3,Cell line enhanced,,CAPAN-2: 43.7;HaCaT: 46.4;SCLC-21H: 41.1
77,GLRB,,ENSG00000109738,Glycine receptor beta,4,157076057-157172090,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA052363,Approved,,,,Renal cancer:4.89e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 62.0;parathyroid gland: 63.1,"cervix, uterine: 14.1",Mixed,,
78,GPR150,PGR11,ENSG00000178015,G protein-coupled receptor 150,5,95620078-95622142,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA026635,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 1.3;parathyroid gland: 2.0,pancreas: 1.0,Cell line enhanced,,ASC diff: 1.0;SiHa: 1.3;TIME: 2.2
79,GPR160,"GPCR1, GPCR150",ENSG00000173890,G protein-coupled receptor 160,3,170037929-170085403,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA006970,Approved,,Supported,Plasma membrane,"Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 435.1,small intestine: 109.0,Cell line enhanced,,THP-1: 130.2;U-266/70: 156.8
80,GPR27,SREB1,ENSG00000170837,G protein-coupled receptor 27,3,71754050-71756496,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA029395,Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Cytosol,"Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 46.5,cerebral cortex: 24.9,Cell line enhanced,,EFO-21: 17.2;HL-60: 14.7;NTERA-2: 30.5;SH-SY5Y: 12.3
81,GPR39,,ENSG00000183840,G protein-coupled receptor 39,2,132416574-132646559,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA022111,Approved,,,,Pancreatic cancer:7.50e-4 (unfavourable),Mixed,Tissue enhanced,,parathyroid gland: 18.5,"cervix, uterine,colon: 6.0",Cell line enhanced,,A-431: 25.5;hTEC/SVTERT24-B: 28.7
82,GREM2,"CKTSF1B2, DAND3, FLJ21195, Prdc",ENSG00000180875,"Gremlin 2, DAN family BMP antagonist",1,240489573-240612149,"Disease related genes, Predicted secreted proteins",Evidence at protein level,CAB009920,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 48.8;parathyroid gland: 78.3,rectum: 22.6,Cell line enhanced,,BJ: 5.1;BJ hTERT+: 5.2;fHDF/TERT166: 25.0
83,GRIK5,"GluK5, GRIK2, KA2",ENSG00000105737,Glutamate ionotropic receptor kainate type subunit 5,19,41998321-42069498,Predicted membrane proteins,Evidence at protein level,HPA074001,,,Supported,Nucleus<br>Plasma membrane,"Pancreatic cancer:7.23e-4 (favourable), Renal cancer:9.32e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 30.8;parathyroid gland: 22.1,testis: 18.8,Cell line enhanced,,HEL: 12.3;NTERA-2: 13.1;REH: 34.1;SCLC-21H: 12.1;SH-SY5Y: 24.1
84,GRM7,"GLUR7, GPRC1G, mGlu7, MGLUR7, PPP1R87",ENSG00000196277,Glutamate metabotropic receptor 7,3,6770001-7741533,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015964,,,Uncertain,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 10.1;parathyroid gland: 7.2,smooth muscle: 3.4,Cell line enriched,12.0,SH-SY5Y: 5.0
85,GUCY1A3,"GC-SA3, GUC1A3",ENSG00000164116,Guanylate cyclase 1 soluble subunit alpha,4,155666711-155732349,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010887, HPA056004, HPA058617",Uncertain,,Supported,Nucleus,"Lung cancer:2.38e-4 (favourable), Testis cancer:3.59e-4 (unfavourable), Renal cancer:7.59e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 136.7,smooth muscle: 43.8,Cell line enhanced,,HAP1: 7.2;Karpas-707: 7.1;MOLT-4: 15.2;RPTEC TERT1: 9.3;RT4: 11.7;SH-SY5Y: 9.5
86,HOOK1,HK1,ENSG00000134709,Hook microtubule tethering protein 1,1,59814786-59876378,Predicted intracellular proteins,Evidence at protein level,"HPA018537, HPA018820",Enhanced,,,,"Colorectal cancer:4.53e-6 (favourable), Head and neck cancer:4.42e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 55.2,testis: 30.1,Cell line enhanced,,EFO-21: 32.6;RPTEC TERT1: 24.3
87,HOXA2,HOX1K,ENSG00000105996,Homeobox A2,7,27100354-27102811,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA078220,,,Approved,Nucleus<br>Vesicles,,Mixed,Tissue enhanced,,parathyroid gland: 8.1,epididymis: 6.2,Cell line enhanced,,AN3-CA: 13.4;HaCaT: 5.3
88,HOXA4,"HOX1, HOX1D",ENSG00000197576,Homeobox A4,7,27128507-27130799,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA060088,Approved,,Enhanced,Nuclear bodies,Endometrial cancer:6.37e-4 (unfavourable),Mixed,Tissue enhanced,,fallopian tube: 37.3;parathyroid gland: 35.3,esophagus: 16.4,Cell line enhanced,,AN3-CA: 26.9;WM-115: 28.7
89,HPSE,"HPA, HPSE1, HSE1",ENSG00000173083,Heparanase,4,83292461-83335153,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB009813, HPA055344",,,Enhanced,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,parathyroid gland: 20.0,testis: 10.0,Cell line enhanced,,Karpas-707: 27.7
90,HYDIN,"CILD5, DKFZp434D0513, KIAA1864, PPP1R31",ENSG00000157423,"HYDIN, axonemal central pair apparatus protein",16,70807378-71230722,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA067155, HPA074129",Enhanced,,Approved,Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,fallopian tube: 9.1;parathyroid gland: 5.4;testis: 6.4,epididymis: 2.6,Cell line enhanced,,RPTEC TERT1: 2.1;SiHa: 6.4
91,IL1RAPL2,"IL-1R9, IL1R9, IL1RAPL-2, TIGIRR-1",ENSG00000189108,Interleukin 1 receptor accessory protein like 2,X,104566315-105767829,Predicted membrane proteins,Evidence at protein level,"HPA036128, HPA036129",Uncertain,,,,,Not detected,Tissue enhanced,,parathyroid gland: 4.8,adrenal gland: 1.9,Cell line enhanced,,fHDF/TERT166: 1.1;hTERT-HME1: 4.3;NTERA-2: 1.0;RT4: 1.6
92,IL4,"BCGF-1, BCGF1, BSF1, IL-4, MGC79402",ENSG00000113520,Interleukin 4,5,132673986-132682676,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA072995,Approved,,,,,Not detected,Tissue enhanced,,parathyroid gland: 1.6,skin: 0.6,Group enriched,6.0,HMC-1: 3.4;MOLT-4: 17.0
93,ILDR1,"DFNB42, MGC50831",ENSG00000145103,Immunoglobulin like domain containing receptor 1,3,121987323-122022204,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA018207,Approved,,,,Renal cancer:5.79e-9 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 35.1,"cervix, uterine: 20.0",Cell line enhanced,,CAPAN-2: 6.5;HDLM-2: 10.3;MCF7: 5.7;RT4: 7.7;T-47d: 6.4;U-266/70: 5.6
94,IQGAP2,,ENSG00000145703,IQ motif containing GTPase activating protein 2,5,76403249-76708132,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004241, HPA037403, HPA037404",Uncertain,,Approved,Vesicles<br>Plasma membrane,"Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 126.8,testis: 92.1,Cell line enhanced,,CACO-2: 61.1;HMC-1: 186.1;RPMI-8226: 56.3
95,ITPR1,"ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29",ENSG00000150995,"Inositol 1,4,5-trisphosphate receptor type 1",3,4493348-4847840,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014765, HPA016487",Approved,,Approved,Vesicles,Thyroid cancer:3.43e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 106.8,thyroid gland: 47.4,Cell line enhanced,,HDLM-2: 75.1;HeLa: 38.4;U-87 MG: 44.6
96,KANK4,"ANKRD38, KIAA0172",ENSG00000132854,KN motif and ankyrin repeat domains 4,1,62236979-62319414,Predicted intracellular proteins,Evidence at protein level,HPA014030,Uncertain,,Uncertain,Microtubules<br>Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 29.5;placenta: 16.4,adipose tissue: 11.8,Cell line enhanced,,BEWO: 32.2;Hep G2: 9.9;SCLC-21H: 7.5
97,KATNAL2,"DKFZP667C165, MGC33211",ENSG00000167216,Katanin catalytic subunit A1 like 2,18,46917492-47102243,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040712, HPA042029",Approved,,Approved,Nucleoplasm<br>Intermediate filaments,Renal cancer:1.24e-7 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 45.1;testis: 32.6,thyroid gland: 24.4,Mixed,,
98,KCNC3,"Kv3.3, SCA13",ENSG00000131398,Potassium voltage-gated channel subfamily C member 3,19,50311937-50333515,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA018041,Approved,,,,Renal cancer:1.23e-4 (unfavourable),Mixed,Tissue enhanced,,parathyroid gland: 39.9,cerebral cortex: 19.8,Cell line enhanced,,HMC-1: 26.4;SK-BR-3: 15.3;T-47d: 18.4;U-2 OS: 13.8
99,KCNIP3,"CSEN, DREAM, KCHIP3",ENSG00000115041,Potassium voltage-gated channel interacting protein 3,2,95297304-95386083,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA069797,Approved,,,,Endometrial cancer:1.58e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 40.6;parathyroid gland: 44.0,thyroid gland: 28.0,Cell line enhanced,,BJ hTERT+: 14.6;RPTEC TERT1: 26.5;U-138 MG: 16.1
100,KCNJ2,"IRK1, Kir2.1, LQT7",ENSG00000123700,Potassium voltage-gated channel subfamily J member 2,17,70168673-70180048,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA029109,Approved,,,,,Mixed,Tissue enhanced,,parathyroid gland: 44.6,fallopian tube: 10.6,Cell line enhanced,,REH: 6.8;RH-30: 28.3;U-138 MG: 10.5
101,KCNJ3,"GIRK1, KGA, Kir3.1",ENSG00000162989,Potassium voltage-gated channel subfamily J member 3,2,154698299-154858352,"Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA024231,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 25.4;parathyroid gland: 39.8,seminal vesicle: 14.1,Cell line enhanced,,BJ: 1.2
102,KCNK13,"K2p13.1, THIK-1, THIK1",ENSG00000152315,Potassium two pore domain channel subfamily K member 13,14,90061765-90185857,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at transcript level,HPA003514,Approved,,Approved,Nuclear speckles<br>Cell Junctions,,Mixed,Tissue enhanced,,parathyroid gland: 14.6;testis: 14.4,kidney: 3.3,Cell line enhanced,,RT4: 1.4
103,KIAA2022,"KIDLIA, MRX98, XPN",ENSG00000050030,KIAA2022,X,74732849-74925485,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,HPA000407,Uncertain,,Uncertain,Nucleoplasm<br>Midbody,,Mixed,Tissue enhanced,,cerebral cortex: 5.4;parathyroid gland: 5.3,prostate: 1.9,Group enriched,6.0,HAP1: 5.0;Karpas-707: 5.9;SiHa: 6.2
104,KLHDC7B,MGC16635,ENSG00000130487,Kelch domain containing 7B,22,50548033-50551023,Predicted intracellular proteins,Evidence at protein level,HPA000518,Uncertain,,,,Breast cancer:1.30e-4 (favourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 12.7,thyroid gland: 3.4,Group enriched,6.0,HHSteC: 18.6;HMC-1: 87.0
105,KLHL14,KIAA1384,ENSG00000197705,Kelch like family member 14,18,32672671-32773062,Predicted intracellular proteins,Evidence at protein level,HPA024777,Uncertain,,Supported,Actin filaments<br>Cytosol,,Group enriched,Tissue enhanced,,parathyroid gland: 19.3;seminal vesicle: 17.9;thyroid gland: 23.0,spleen: 11.7,Cell line enhanced,,Hep G2: 10.5;REH: 3.8;RPTEC TERT1: 6.3;SCLC-21H: 3.7
106,KLRG2,"CLEC15B, FLJ44186",ENSG00000188883,Killer cell lectin like receptor G2,7,139452690-139483712,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018199,Uncertain,,,,Lung cancer:8.61e-4 (favourable),Tissue enriched,Tissue enhanced,,lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.8,kidney: 2.7,Cell line enhanced,,BEWO: 14.0;HAP1: 15.9;SCLC-21H: 8.6;SK-BR-3: 23.3
107,LCA5,C6orf152,ENSG00000135338,"LCA5, lebercilin",6,79484991-79537458,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA029053, HPA029055",Supported,,,,Renal cancer:4.69e-4 (unfavourable),Mixed,Tissue enhanced,,parathyroid gland: 48.1,fallopian tube: 15.6,Cell line enhanced,,HEL: 13.2
108,LRFN5,"C14orf146, FIGLER8, SALM5",ENSG00000165379,Leucine rich repeat and fibronectin type III domain containing 5,14,41607570-41904549,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA001177,Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 52.3,"cervix, uterine: 16.8",Cell line enhanced,,AN3-CA: 16.8;RPTEC TERT1: 4.6;SCLC-21H: 11.1;U-138 MG: 11.4
109,LRRC24,LRRC14OS,ENSG00000254402,Leucine rich repeat containing 24,8,144522377-144527032,Predicted membrane proteins,Evidence at protein level,"HPA028171, HPA052250",Enhanced,,Approved,Vesicles,,Not detected,Tissue enhanced,,parathyroid gland: 3.6;prostate: 4.5,cerebral cortex: 3.1,Cell line enhanced,,SCLC-21H: 3.2;SH-SY5Y: 7.9
110,LRRC9,FLJ46156,ENSG00000131951,Leucine rich repeat containing 9,14,59919713-60063559,Predicted intracellular proteins,Evidence at transcript level,"HPA040965, HPA041381",Uncertain,,,,,Not detected,Tissue enhanced,,parathyroid gland: 3.5;testis: 10.8,fallopian tube: 1.9,Cell line enhanced,,NTERA-2: 1.0
111,LRRN2,"FIGLER7, GAC1, LRANK1, LRRN5",ENSG00000170382,Leucine rich repeat neuronal 2,1,204617170-204685733,Predicted membrane proteins,Evidence at transcript level,HPA029124,Uncertain,,Approved,Endoplasmic reticulum,Endometrial cancer:2.59e-7 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 23.4;parathyroid gland: 21.2,fallopian tube: 11.5,Cell line enhanced,,HEL: 8.3;NTERA-2: 17.9;RPMI-8226: 20.1;T-47d: 9.4
112,LURAP1,"C1orf190, FLJ25163, LRAP35a",ENSG00000171357,Leucine rich adaptor protein 1,1,46203334-46221261,Predicted intracellular proteins,Evidence at protein level,"HPA030060, HPA030061",Uncertain,,Approved,Vesicles,Renal cancer:8.81e-8 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 18.1;thyroid gland: 17.6,testis: 9.2,Mixed,,
113,MAF,c-MAF,ENSG00000178573,MAF bZIP transcription factor,16,79585843-79600714,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB010296, HPA028289",Approved,,,,Renal cancer:3.74e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 149.6,small intestine: 91.3,Group enriched,9.0,Karpas-707: 148.6;RPMI-8226: 242.2
114,MAGI2,"ACVRIP1, AIP1, ARIP1, KIAA0705, MAGI-2",ENSG00000187391,"Membrane associated guanylate kinase, WW and PDZ domain containing 2",7,78017057-79453574,Predicted intracellular proteins,Evidence at protein level,HPA013650,Approved,,,,Renal cancer:1.08e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 46.2;parathyroid gland: 38.6,prostate: 14.0,Group enriched,5.0,AF22: 19.3;Karpas-707: 58.7
115,MALL,BENE,ENSG00000144063,"Mal, T-cell differentiation protein like",2,110083870-110116566,Predicted membrane proteins,Evidence at protein level,HPA051410,Uncertain,,,,Pancreatic cancer:1.23e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 222.2;parathyroid gland: 321.0,small intestine: 182.4,Cell line enhanced,,A-431: 176.6;A549: 174.8;CAPAN-2: 233.6;fHDF/TERT166: 228.9;HaCaT: 183.5
116,MAP9,"ASAP, FLJ21159",ENSG00000164114,Microtubule associated protein 9,4,155342658-155376970,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,parathyroid gland: 79.9,cerebral cortex: 27.1,Cell line enhanced,,SH-SY5Y: 44.7
117,MAPK4,"Erk3-related, Erk4, PRKM4",ENSG00000141639,Mitogen-activated protein kinase 4,18,50560078-50731824,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,adrenal gland: 29.7;cerebral cortex: 33.4;parathyroid gland: 60.1,seminal vesicle: 13.9,Cell line enhanced,,SCLC-21H: 13.6;SH-SY5Y: 3.0
118,MARC2,"FLJ20605, MOSC2",ENSG00000117791,Mitochondrial amidoxime reducing component 2,1,220748225-220784815,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015085, HPA017572",Enhanced,,,,"Liver cancer:1.40e-10 (favourable), Renal cancer:3.09e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 338.5,kidney: 139.5,Cell line enhanced,,T-47d: 33.9
119,MBOAT2,"FLJ14415, FLJ90298, OACT2",ENSG00000143797,Membrane bound O-acyltransferase domain containing 2,2,8852690-9003813,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014836,Uncertain,,Approved,Vesicles,"Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 50.1,cerebral cortex: 29.7,Mixed,,
120,MCC,,ENSG00000171444,Mutated in colorectal cancers,5,113022099-113488830,Predicted intracellular proteins,Evidence at protein level,"HPA037390, HPA037391",Approved,Approved,Supported,Nucleoplasm,Renal cancer:6.19e-4 (favourable),Expressed in all,Tissue enhanced,,ovary: 87.5;parathyroid gland: 66.9,skin: 25.1,Cell line enhanced,,HBEC3-KT: 39.0
121,MCOLN3,"FLJ11006, TRP-ML3, TRPML3",ENSG00000055732,Mucolipin 3,1,85018082-85048499,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA018106, HPA062137",Enhanced,,Approved,Nucleoli<br>Cytosol,,Tissue enriched,Tissue enhanced,,adrenal gland: 57.8;parathyroid gland: 42.8,epididymis: 17.5,Cell line enhanced,,HAP1: 13.4;RH-30: 15.2;SK-MEL-30: 22.2
122,MELTF,"CD228, FLJ38863, MAP97, MFI2, MGC4856, MTf, MTF1",ENSG00000163975,Melanotransferrin,3,196988621-197029816,"CD markers, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004880,Approved,,,,Renal cancer:6.99e-11 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 32.3;salivary gland: 28.2,small intestine: 9.6,Cell line enhanced,,A-431: 140.8;SK-MEL-30: 152.3
123,METTL18,"AsTP2, C1orf156, HPM1, MGC9084",ENSG00000171806,Methyltransferase like 18,1,169792529-169794966,Predicted intracellular proteins,Evidence at protein level,HPA035314,Approved,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:1.01e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable), Renal cancer:4.06e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 44.5,lymph node: 15.3,Expressed in all,,
124,MPP2,"DKFZp761D0712, DLG2",ENSG00000108852,Membrane palmitoylated protein 2,17,43875357-43909711,Predicted intracellular proteins,Evidence at protein level,HPA026486,Approved,,Approved,Mitochondria<br>Cytosol,Endometrial cancer:1.87e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 37.9;epididymis: 33.0;parathyroid gland: 43.8,testis: 24.0,Mixed,,
125,MTMR7,,ENSG00000003987,Myotubularin related protein 7,8,17298030-17413528,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 22.9;parathyroid gland: 15.2,thyroid gland: 5.5,Cell line enhanced,,SCLC-21H: 12.4;SH-SY5Y: 6.5
126,NAALADL2,,ENSG00000177694,N-acetylated alpha-linked acidic dipeptidase like 2,3,174438573-175810552,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012413, HPA017425, CAB025586",Approved,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,parathyroid gland: 28.0,"cervix, uterine: 9.9",Cell line enhanced,,ASC TERT1: 10.1;fHDF/TERT166: 5.0;WM-115: 5.8
127,NCR3LG1,"B7-H6, DKFZp686O24166",ENSG00000188211,Natural killer cell cytotoxicity receptor 3 ligand 1,11,17351726-17377341,Predicted membrane proteins,Evidence at protein level,HPA024137,Uncertain,,,,Renal cancer:4.21e-12 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 12.9,rectum: 5.6,Cell line enhanced,,HL-60: 42.1
128,NEDD8-MDP1,,ENSG00000255526,NEDD8-MDP1 readthrough,14,24213955-24232352,Predicted intracellular proteins,Evidence at protein level,"HPA003064, HPA060254",Uncertain,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,parathyroid gland: 2.7,testis: 1.8,Cell line enhanced,,MOLT-4: 6.6
129,NPM2,,ENSG00000158806,Nucleophosmin/nucleoplasmin 2,8,22024125-22036897,Predicted intracellular proteins,Evidence at protein level,HPA041070,Enhanced,,Approved,Nucleus<br>Nucleoli,"Renal cancer:3.18e-6 (favourable), Pancreatic cancer:9.02e-4 (favourable)",Tissue enhanced,Tissue enhanced,,parathyroid gland: 69.7;thyroid gland: 42.7,cerebral cortex: 31.8,Cell line enhanced,,HaCaT: 15.6;HEL: 13.0;Hep G2: 21.9
130,NRG2,"Don-1, HRG2, NTAK",ENSG00000158458,Neuregulin 2,5,139846779-140043299,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,"HPA038935, HPA047973",Uncertain,,Supported,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,parathyroid gland: 13.3,ovary: 10.2,Cell line enhanced,,AN3-CA: 7.0;PC-3: 12.4;SCLC-21H: 5.8
131,NUAK1,"ARK5, KIAA0537, NuaK1",ENSG00000074590,NUAK family kinase 1,12,106063340-106140033,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA057143,,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Microtubules,"Stomach cancer:4.27e-4 (unfavourable), Endometrial cancer:9.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 47.0;parathyroid gland: 42.5,skin: 21.0,Cell line enhanced,,AF22: 50.0;EFO-21: 47.3;RH-30: 70.1
132,OGDHL,FLJ10851,ENSG00000197444,Oxoglutarate dehydrogenase-like,10,49734643-49762379,"Citric acid cycle related proteins, Predicted intracellular proteins",Evidence at protein level,HPA052497,Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,Renal cancer:1.21e-14 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 128.4;parathyroid gland: 56.3,liver: 41.6,Cell line enhanced,,AN3-CA: 19.8;RPTEC TERT1: 32.9;SH-SY5Y: 17.3
133,OGN,"mimecan, OIF, SLRR3A",ENSG00000106809,Osteoglycin,9,92383967-92404696,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA013132,Approved,,Supported,Endoplasmic reticulum,"Renal cancer:1.92e-4 (unfavourable), Urothelial cancer:2.03e-4 (unfavourable), Ovarian cancer:4.04e-4 (unfavourable)",Mixed,Tissue enhanced,,"cervix, uterine: 374.3;parathyroid gland: 604.4",gallbladder: 276.4,Cell line enhanced,,ASC TERT1: 17.1;HSkMC: 8.0;MOLT-4: 27.9
134,OPN4,"melanopsin, MOP",ENSG00000122375,Opsin 4,10,86654557-86666848,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA039147,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.2;parathyroid gland: 1.4,skeletal muscle: 0.9,Not detected,,
135,OR7A5,HTPCR2,ENSG00000188269,Olfactory receptor family 7 subfamily A member 5,19,14792490-14835376,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA053823,Uncertain,,,,,Tissue enriched,Tissue enhanced,,epididymis: 5.5;parathyroid gland: 5.4;testis: 2.8,"breast,seminal vesicle: 0.9",Not detected,,
136,OR7C1,"OR19-5, OR7C4",ENSG00000127530,Olfactory receptor family 7 subfamily C member 1,19,14799146-14800211,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA047127,Uncertain,,,,,Tissue enriched,Tissue enhanced,,epididymis: 3.5;parathyroid gland: 5.0;testis: 3.9,seminal vesicle: 1.5,Not detected,,
137,P3H3,"GRCB, HSU47926, LEPREL2",ENSG00000110811,Prolyl 3-hydroxylase 3,12,6828410-6839851,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA043695,Approved,,Approved,Nucleoli<br>Plasma membrane<br>Cytosol,"Renal cancer:1.64e-4 (unfavourable), Pancreatic cancer:4.91e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 11.7,endometrium: 6.2,Cell line enhanced,,BJ: 33.3
138,PABPC4L,,ENSG00000254535,Poly(A) binding protein cytoplasmic 4 like,4,134196333-134201748,Predicted intracellular proteins,Evidence at protein level,,,,,,Renal cancer:1.11e-5 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 12.8;placenta: 14.7,endometrium: 6.4,Cell line enhanced,,HAP1: 11.9;HeLa: 10.3;REH: 7.4;RH-30: 8.3;U-2 OS: 9.1
139,PAQR4,FLJ30002,ENSG00000162073,Progestin and adipoQ receptor family member 4,16,2969245-2973489,Predicted membrane proteins,Evidence at protein level,HPA068394,,,Approved,Vesicles,"Renal cancer:3.01e-6 (unfavourable), Stomach cancer:1.70e-4 (favourable), Liver cancer:6.86e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 54.0;parathyroid gland: 65.2,"prostate,skin: 19.2",Mixed,,
140,PCDH11X,"PCDH-X, PCDH11, PCDHX, PPP1R119",ENSG00000102290,Protocadherin 11 X-linked,X,91779261-92623230,Predicted membrane proteins,Evidence at transcript level,HPA000432,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 4.6;ovary: 8.9;parathyroid gland: 4.9,"cervix, uterine: 1.5",Cell line enhanced,,AF22: 1.4;AN3-CA: 2.1
141,PCDHA11,"CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11",ENSG00000249158,Protocadherin alpha 11,5,140868183-141012344,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA077160,,,Approved,Vesicles<br>Cell Junctions<br>Cytoplasmic bodies,,Not detected,Tissue enhanced,,cerebral cortex: 7.6;parathyroid gland: 3.8,testis: 1.8,Cell line enhanced,,AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
142,PCDHB11,"ME2, PCDH-BETA11",ENSG00000197479,Protocadherin beta 11,5,141199582-141203779,Predicted membrane proteins,Evidence at transcript level,HPA045042,Uncertain,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,parathyroid gland: 8.2,endometrium: 2.5,Cell line enhanced,,AN3-CA: 5.1;EFO-21: 7.4
143,PCDHB16,"KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a",ENSG00000272674,Protocadherin beta 16,5,141181399-141186399,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014668,,,Approved,Vesicles<br>Plasma membrane,,Mixed,Tissue enhanced,,parathyroid gland: 10.8,ovary: 7.3,Cell line enhanced,,AN3-CA: 15.6;U-138 MG: 35.8
144,PCDHB6,PCDH-BETA6,ENSG00000113211,Protocadherin beta 6,5,141150022-141153287,Predicted membrane proteins,Evidence at transcript level,HPA029566,Uncertain,,Uncertain,Nucleus<br>Plasma membrane<br>Cytosol,Renal cancer:5.52e-4 (unfavourable),Mixed,Tissue enhanced,,parathyroid gland: 7.1,testis: 3.5,Cell line enhanced,,EFO-21: 15.4;SH-SY5Y: 7.4;T-47d: 5.0;U-2197: 7.0;WM-115: 10.2
145,PCDHGB5,PCDH-GAMMA-B5,ENSG00000276547,"Protocadherin gamma subfamily B, 5",5,141397987-141512979,Predicted membrane proteins,Evidence at protein level,"HPA008755, HPA010580",Uncertain,,Approved,Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 19.8,thyroid gland: 7.6,Cell line enhanced,,ASC diff: 45.6;ASC TERT1: 34.8;BJ hTERT+ SV40 Large T+: 27.3;BJ hTERT+ SV40 Large T+ RasG12V: 31.8
146,PCYOX1L,MGC3265,ENSG00000145882,Prenylcysteine oxidase 1 like,5,149358007-149369653,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037463, HPA038402",Approved,,Approved,Nucleoplasm<br>Mitochondria,,Expressed in all,Tissue enhanced,,parathyroid gland: 21.4,cerebral cortex: 12.5,Mixed,,
147,PDE11A,,ENSG00000128655,Phosphodiesterase 11A,2,177623252-178108339,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA034560,Approved,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 10.5;prostate: 8.8,testis: 6.4,Cell line enhanced,,fHDF/TERT166: 2.2;Hep G2: 2.0
148,PDGFC,"fallotein, SCDGF",ENSG00000145431,Platelet derived growth factor C,4,156760454-156971394,"Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA009134,Approved,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 40.6,endometrium: 16.8,Cell line enhanced,,fHDF/TERT166: 47.4;U-138 MG: 41.4
149,PHGDH,"PDG, PGDH, SERA",ENSG00000092621,Phosphoglycerate dehydrogenase,1,119659798-119744215,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003681, HPA021241, HPA024031, CAB068216",Enhanced,,Enhanced,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 216.7,skin: 115.9,Mixed,,
150,PHKA1,PHKA,ENSG00000067177,Phosphorylase kinase regulatory subunit alpha 1,X,72578814-72714319,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA001081,Enhanced,,Approved,Vesicles,Endometrial cancer:6.84e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 40.1;skeletal muscle: 35.5,adrenal gland: 15.6,Mixed,,
151,PIP5KL1,"bA203J24.5, MGC46424",ENSG00000167103,Phosphatidylinositol-4-phosphate 5-kinase like 1,9,127920879-127930797,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA056240,Uncertain,,Supported,Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 3.8,skin: 2.2,Cell line enhanced,,Karpas-707: 32.1;RPMI-8226: 21.0
152,PLA2G4A,"cPLA2-alpha, PLA2G4",ENSG00000116711,Phospholipase A2 group IVA,1,186828953-186988981,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010050, HPA050062, HPA054206",Approved,,Supported,Cytosol,"Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 200.5,seminal vesicle: 68.3,Cell line enhanced,,RPMI-8226: 50.7;U-2197: 61.7
153,PLCB1,"KIAA0581, PLC-I, PLC154",ENSG00000182621,Phospholipase C beta 1,20,8077251-8968360,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004275, CAB005334, HPA034743, HPA057910",Enhanced,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 68.3;parathyroid gland: 121.3,placenta: 28.2,Cell line enhanced,,Hep G2: 46.8
154,PLEKHD1,UPF0639,ENSG00000175985,Pleckstrin homology and coiled-coil domain containing D1,14,69484692-69531551,Predicted intracellular proteins,Evidence at protein level,HPA051875,Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 2.8;thyroid gland: 2.7,epididymis: 2.0,Cell line enhanced,,SK-BR-3: 1.8;T-47d: 2.1
155,PLXNA1,"NOV, PLXN1",ENSG00000114554,Plexin A1,3,126988594-127037392,Predicted membrane proteins,Evidence at protein level,"HPA007499, CAB012483",Uncertain,,Enhanced,Nucleus<br>Cytosol,"Liver cancer:4.13e-6 (unfavourable), Renal cancer:5.64e-5 (unfavourable), Ovarian cancer:1.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 43.5,skin: 16.8,Mixed,,
156,PPM1H,"ARHCL1, FLJ13253, KIAA1157, NERPP-2C",ENSG00000111110,"Protein phosphatase, Mg2+/Mn2+ dependent 1H",12,62643982-62935037,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB020694, HPA044244, HPA058777",Approved,,Supported,Nucleoplasm,Renal cancer:2.72e-5 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 54.2,cerebral cortex: 23.0,Cell line enhanced,,CACO-2: 67.4;HMC-1: 56.0
157,PPM1L,PP2CE,ENSG00000163590,"Protein phosphatase, Mg2+/Mn2+ dependent 1L",3,160755602-161078907,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA019891, HPA019953",Approved,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:4.90e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 39.6,cerebral cortex: 27.9,Group enriched,5.0,HDLM-2: 73.7;U-266/70: 57.7
158,PPY,PNP,ENSG00000108849,Pancreatic polypeptide,17,43940804-43942468,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016735, HPA032122",Enhanced,,,,,Tissue enriched,Tissue enhanced,,pancreas: 35.3;parathyroid gland: 33.7,"rectum,skin: 8.3",Cell line enhanced,,BEWO: 3.6;EFO-21: 3.2;U-2 OS: 4.0
159,PRKD1,"PKC-mu, PKCM, PKD, PRKCM",ENSG00000184304,Protein kinase D1,14,29576479-30191898,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB018367, HPA029834",Uncertain,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 50.3,prostate: 28.5,Mixed,,
160,PRRT3,FLJ33674,ENSG00000163704,Proline rich transmembrane protein 3,3,9945542-9952394,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA035127, HPA035128",Uncertain,,Approved,Nucleus<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 19.4;parathyroid gland: 27.8,fallopian tube: 12.2,Cell line enhanced,,MCF7: 17.7;SK-BR-3: 25.1
161,PRSS45,TESSP5,ENSG00000188086,"Protease, serine 45",3,46742092-46744755,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA060284,Uncertain,,,,,Mixed,Tissue enhanced,,epididymis: 9.8;parathyroid gland: 8.6,skeletal muscle: 3.7,Not detected,,
162,PRSS50,"CT20, TSP50",ENSG00000206549,"Protease, serine 50",3,46712115-46812574,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA040768,Supported,,,,,Mixed,Tissue enhanced,,epididymis: 5.7;parathyroid gland: 4.1,"skeletal muscle,testis,thyroid gland: 2.0",Not detected,,
163,PTN,"HBGF8, HBNF, NEGF1",ENSG00000105894,Pleiotrophin,7,137227341-137343865,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,CAB017685,Enhanced,,,,Renal cancer:1.35e-4 (favourable),Tissue enriched,Tissue enhanced,,parathyroid gland: 725.3,cerebral cortex: 269.6,Cell line enriched,12.0,AF22: 1551.5
164,PTPRD,"HPTP, PTPD",ENSG00000153707,"Protein tyrosine phosphatase, receptor type D",9,8314246-10612723,"Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054829,Uncertain,,Approved,Vesicles,Renal cancer:7.45e-6 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 32.7;parathyroid gland: 47.0,ovary: 11.7,Cell line enhanced,,AF22: 27.3;RH-30: 9.9
165,PTPRG,"PTPG, RPTPG",ENSG00000144724,"Protein tyrosine phosphatase, receptor type G",3,61561569-62297613,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA064237,Uncertain,,,,Renal cancer:3.10e-6 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 73.5,thyroid gland: 22.8,Mixed,,
166,PYGO1,,ENSG00000171016,Pygopus family PHD finger 1,15,55538890-55588947,Predicted intracellular proteins,Evidence at protein level,HPA042248,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 29.9,thyroid gland: 12.0,Cell line enhanced,,U-698: 23.4
167,RAB6C,WTH3,ENSG00000222014,"RAB6C, member RAS oncogene family",2,129979664-129982738,Predicted intracellular proteins,Evidence at protein level,HPA059131,Uncertain,,Uncertain,Golgi apparatus,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 7.5,breast: 3.2,Group enriched,6.0,BEWO: 2.4;HMC-1: 1.9;REH: 4.9;T-47d: 3.0;U-266/70: 1.6
168,RASL11B,,ENSG00000128045,RAS like family 11 member B,4,52862290-52866835,Predicted intracellular proteins,Evidence at transcript level,HPA057803,Uncertain,,Approved,Nuclear bodies,,Mixed,Tissue enhanced,,ovary: 26.0;parathyroid gland: 30.1,cerebral cortex: 13.5,Cell line enhanced,,BEWO: 13.0;NTERA-2: 14.5;SH-SY5Y: 38.8
169,RAX2,"ARMD6, CORD11, MGC15631, RAXL1",ENSG00000173976,Retina and anterior neural fold homeobox 2,19,3769089-3772221,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA052533,Uncertain,,,,,Not detected,Tissue enhanced,,parathyroid gland: 1.2,fallopian tube: 0.7,Not detected,,
170,RELL2,"C5orf16, FLJ90583",ENSG00000164620,RELT like 2,5,141636950-141641077,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA077928,,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 13.2;parathyroid gland: 23.3,testis: 4.3,Mixed,,
171,REM2,FLJ38964,ENSG00000139890,RRAD and GEM like GTPase 2,14,22883165-22887686,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,bone marrow: 6.0;parathyroid gland: 4.6,testis: 2.9,Cell line enhanced,,AF22: 3.0
172,RIMBP2,"KIAA0318, MGC15831, PPP1R133, RBP2, RIM-BP2",ENSG00000060709,RIMS binding protein 2,12,130396137-130517917,Predicted intracellular proteins,Evidence at protein level,,,,,,Pancreatic cancer:4.16e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 95.0,cerebral cortex: 24.4,Group enriched,10.0,SCLC-21H: 26.1;SH-SY5Y: 41.8
173,RNF165,"ARKL2, RNF111L2",ENSG00000141622,Ring finger protein 165,18,46326809-46463140,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041615, HPA047798",Uncertain,,Approved,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 9.3;parathyroid gland: 9.8,thyroid gland: 7.0,Cell line enhanced,,AF22: 13.9;SCLC-21H: 17.1;SH-SY5Y: 17.5
174,RNF180,,ENSG00000164197,Ring finger protein 180,5,64165844-64372869,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006897,Approved,,Approved,Cytosol,Renal cancer:6.81e-5 (favourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 62.4,thyroid gland: 24.8,Cell line enriched,5.0,RPMI-8226: 20.6
175,ROR1,NTRKR1,ENSG00000185483,Receptor tyrosine kinase like orphan receptor 1,1,63774022-64181498,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA057016,,,Uncertain,Microtubules<br>Cytokinetic bridge,,Mixed,Tissue enhanced,,parathyroid gland: 52.0,endometrium: 12.1,Cell line enhanced,,ASC TERT1: 35.2;NTERA-2: 43.3
176,ROR2,"BDB, BDB1, NTRKR2",ENSG00000169071,Receptor tyrosine kinase like orphan receptor 2,9,91563091-91950162,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA021868,Uncertain,,,,"Thyroid cancer:4.28e-8 (unfavourable), Renal cancer:9.86e-7 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 35.1,endometrium: 21.4,Cell line enhanced,,AF22: 25.3;HHSteC: 55.3;HSkMC: 39.9;U-266/70: 29.6
177,RP1-5O6.7,,ENSG00000283900,Casein kinase I isoform epsilon ,22,38291918-38398522,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026288,Uncertain,,,,,,Tissue enhanced,,parathyroid gland: 6.5,cerebral cortex: 2.6,Cell line enhanced,,Karpas-707: 5.1
178,RP11-382A20.3,,ENSG00000166503,Hepatoma-derived growth factor-related protein 3 ,15,83112738-83208018,Predicted intracellular proteins,Evidence at protein level,HPA040719,Approved,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,parathyroid gland: 33.0,cerebral cortex: 19.5,Mixed,,
179,RP11-407N17.3,,ENSG00000258941,CTAGE family member 5 isoform 8 precursor ,14,39233902-39350423,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922, HPA054066, HPA055459",Uncertain,,Approved,Endoplasmic reticulum,,Not detected,Tissue enhanced,,duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5,kidney: 19.0,Cell line enhanced,,CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0
180,RP11-475E11.9,,ENSG00000274068,,1,108837660-108963484,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,parathyroid gland: 1.5,"adrenal gland,cerebral cortex: 0.9",Cell line enhanced,,HDLM-2: 1.8
181,RP11-511P7.7,,ENSG00000284041,,7,150368790-150396915,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,parathyroid gland: 2.1,endometrium: 1.0,Cell line enhanced,,RPMI-8226: 4.0;SH-SY5Y: 5.5
182,RP11-514P8.7,,ENSG00000270249,,7,102541501-102592444,Predicted intracellular proteins,Evidence at transcript level,HPA046970,Uncertain,,Uncertain,Nucleoplasm,,Not detected,Tissue enhanced,,parathyroid gland: 3.9,"duodenum,epididymis: 1.0",Not detected,,
183,RP11-548K23.11,,ENSG00000249967,,10,97584374-97673910,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,parathyroid gland: 1.6,"cerebral cortex,seminal vesicle: 0.9",Cell line enhanced,,AN3-CA: 1.0;EFO-21: 1.1
184,RP11-726G1.1,,ENSG00000214776,,12,9467552-9576275,Predicted secreted proteins,Evidence at transcript level,,,,,,,Group enriched,Tissue enhanced,,parathyroid gland: 1.0;testis: 1.8,"endometrium,lymph node: 0.4",Cell line enhanced,,U-698: 4.3;WM-115: 2.1
185,RPS6KA6,RSK4,ENSG00000072133,Ribosomal protein S6 kinase A6,X,84058346-84187907,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA002852, HPA003904",Uncertain,,Supported,Nucleus<br>Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,parathyroid gland: 18.9;thyroid gland: 21.9,kidney: 8.9,Cell line enhanced,,PC-3: 13.7;RH-30: 17.3;SH-SY5Y: 15.2
186,RYR3,,ENSG00000198838,Ryanodine receptor 3,15,33310945-33866121,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA062004,,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 29.1,cerebral cortex: 7.0,Cell line enhanced,,A549: 3.9;RH-30: 6.3;RPTEC TERT1: 2.3
187,SACS,"ARSACS, DKFZp686B15167, DNAJC29, KIAA0730, PPP1R138, SPAX6",ENSG00000151835,Sacsin molecular chaperone,13,23328826-23411513,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB017714,Uncertain,,,,"Renal cancer:6.21e-6 (unfavourable), Endometrial cancer:9.04e-4 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 32.5,cerebral cortex: 16.0,Mixed,,
188,SALL2,"Hsal2, KIAA0360, ZNF795",ENSG00000165821,Spalt like transcription factor 2,14,21521081-21537216,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA004162,Approved,,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:1.23e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)",Mixed,Tissue enhanced,,parathyroid gland: 67.9,cerebral cortex: 42.4,Cell line enhanced,,AF22: 123.9;NTERA-2: 95.1;SCLC-21H: 50.0
189,SAMD5,dJ875H10.1,ENSG00000203727,Sterile alpha motif domain containing 5,6,147508927-147737547,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067811,Uncertain,,Supported,Vesicles,Liver cancer:2.23e-4 (unfavourable),Mixed,Tissue enhanced,,parathyroid gland: 22.5,placenta: 18.1,Cell line enhanced,,Hep G2: 44.5;K-562: 40.0;RH-30: 28.7;WM-115: 20.8
190,SCG5,"7B2, SGNE1, SgV",ENSG00000166922,Secretogranin V,15,32641676-32697098,Predicted secreted proteins,Evidence at protein level,"HPA013136, HPA074618",Enhanced,,,,"Renal cancer:4.51e-9 (unfavourable), Head and neck cancer:9.64e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 233.7;parathyroid gland: 192.7,adrenal gland: 80.4,Group enriched,6.0,HHSteC: 22.6;HSkMC: 24.3;NTERA-2: 15.6;SCLC-21H: 37.1;SH-SY5Y: 38.6;U-87 MG: 46.3
191,SEC14L6,,ENSG00000214491,SEC14 like lipid binding 6,22,30522799-30546682,Predicted intracellular proteins,Evidence at transcript level,HPA067695,,,Approved,Nucleoplasm,,Tissue enriched,Tissue enhanced,,epididymis: 25.8;parathyroid gland: 46.1,lung: 17.8,Cell line enhanced,,K-562: 11.1;RPTEC TERT1: 16.7;SiHa: 7.0
192,SELE,"CD62E, ELAM, ELAM1, ESEL",ENSG00000007908,Selectin E,1,169722641-169764705,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB002143,Enhanced,,,,,Mixed,Tissue enhanced,,parathyroid gland: 45.2;prostate: 46.4,urinary bladder: 27.8,Cell line enriched,6.0,HUVEC TERT2: 1.0
193,SEZ6L2,"FLJ90517, PSK-1",ENSG00000174938,Seizure related 6 homolog like 2,16,29871159-29899547,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA064471,Enhanced,,,,"Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 82.4;parathyroid gland: 58.4,adrenal gland: 30.6,Cell line enhanced,,EFO-21: 72.2
194,SGPP2,"FLJ39004, SPP2",ENSG00000163082,Sphingosine-1-phosphate phosphatase 2,2,222424517-222560948,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:1.28e-4 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 59.2,thyroid gland: 33.7,Cell line enhanced,,CAPAN-2: 13.9;EFO-21: 12.7;hTCEpi: 31.0;RPTEC TERT1: 32.2;SCLC-21H: 20.4
195,SGSM1,"KIAA1941, RUTBC2",ENSG00000167037,Small G protein signaling modulator 1,22,24806169-24927578,Predicted intracellular proteins,Evidence at protein level,HPA003986,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 14.8;parathyroid gland: 19.0,fallopian tube: 7.6,Cell line enhanced,,RPMI-8226: 1.5;SCLC-21H: 2.4;SH-SY5Y: 1.4
196,SKIDA1,"C10orf140, FLJ45187",ENSG00000180592,SKI/DACH domain containing 1,10,21513478-21526368,Predicted intracellular proteins,Evidence at protein level,"HPA039208, HPA040439",Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 3.9,testis: 3.1,Cell line enhanced,,AF22: 25.8;BEWO: 11.6
197,SLC16A11,"FLJ90193, MCT11",ENSG00000174326,Solute carrier family 16 member 11,17,7041630-7043923,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,"Renal cancer:3.19e-7 (favourable), Pancreatic cancer:1.45e-5 (favourable), Liver cancer:2.56e-4 (favourable)",Tissue enhanced,Tissue enhanced,,fallopian tube: 8.9;parathyroid gland: 11.0,seminal vesicle: 3.8,Not detected,,
198,SLC2A13,HMIT,ENSG00000151229,Solute carrier family 2 member 13,12,39755021-40106089,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA006584,Approved,,Approved,Nuclear membrane,,Mixed,Tissue enhanced,,cerebral cortex: 49.3;parathyroid gland: 74.7,"cervix, uterine: 20.4",Mixed,,
199,SLC36A1,"LYAAT-1, PAT1, TRAMD3",ENSG00000123643,Solute carrier family 36 member 1,5,151437046-151492381,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA035937,Approved,,,,"Renal cancer:1.83e-6 (unfavourable), Liver cancer:6.30e-5 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 65.4,duodenum: 44.3,Mixed,,
200,SLC7A2,"ATRC2, CAT-2, HCAT2",ENSG00000003989,Solute carrier family 7 member 2,8,17497088-17570573,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA009277,,,Supported,Plasma membrane<br>Cell Junctions,"Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 380.7,liver: 92.6,Cell line enhanced,,HHSteC: 171.6
201,SLFN13,FLJ31952,ENSG00000154760,Schlafen family member 13,17,35435096-35448837,Predicted intracellular proteins,Evidence at protein level,"HPA022532, HPA023064",Uncertain,,Approved,Cytokinetic bridge,Cervical cancer:3.82e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 41.2,fallopian tube: 26.9,Cell line enhanced,,HL-60: 104.7;REH: 68.4;U-266/70: 48.2
202,SMIM10,CXorf69,ENSG00000184785,Small integral membrane protein 10,X,134990938-134992473,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:3.69e-6 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 63.4;testis: 50.6,fallopian tube: 17.7,Mixed,,
203,SRGAP2C,SRGAP2P1,ENSG00000171943,SLIT-ROBO Rho GTPase activating protein 2C,1,121184810-121392822,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,parathyroid gland: 34.2,skin: 18.1,Cell line enhanced,,WM-115: 78.0
204,STAC,STAC1,ENSG00000144681,SH3 and cysteine rich domain,3,36380344-36548007,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA035143,Uncertain,,Uncertain,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,parathyroid gland: 23.4;prostate: 21.7,lung: 15.8,Cell line enhanced,,fHDF/TERT166: 34.6;HaCaT: 28.9;SH-SY5Y: 48.5;U-87 MG: 45.7
205,STEAP3,"dudlin-2, STMP3, TSAP6",ENSG00000115107,STEAP3 metalloreductase,2,119223831-119265652,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA050510,Uncertain,,Approved,Nucleoli<br>Cytosol,Renal cancer:0.00e+0 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 194.5,liver: 53.0,Cell line enhanced,,U-87 MG: 145.7
206,SV2A,"KIAA0736, SV2",ENSG00000159164,Synaptic vesicle glycoprotein 2A,1,149903318-149917882,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB002226, HPA007863",Enhanced,,Approved,Cytosol,Renal cancer:3.22e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 166.9;parathyroid gland: 72.0,epididymis: 28.2,Cell line enhanced,,NTERA-2: 65.6;SCLC-21H: 63.2
207,SYNE4,"C19orf46, DFNB76, FLJ36445, Nesp4, Nesprin-4",ENSG00000181392,Spectrin repeat containing nuclear envelope family member 4,19,36003307-36008793,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060253,Uncertain,,,,Renal cancer:8.64e-9 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 18.7,prostate: 11.8,Cell line enhanced,,CACO-2: 27.6;Hep G2: 20.0;MCF7: 26.0;SK-BR-3: 30.3;T-47d: 29.1
208,SYT17,,ENSG00000103528,Synaptotagmin 17,16,19167971-19268334,Predicted intracellular proteins,Evidence at protein level,HPA042059,,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 39.8;parathyroid gland: 32.6,prostate: 14.9,Cell line enhanced,,BEWO: 13.7;CAPAN-2: 24.6;MCF7: 16.6
209,TANC2,"DKFZP564D166, FLJ10215, FLJ11824, KIAA1148, KIAA1636, rols, ROLSA",ENSG00000170921,"Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2",17,63009556-63427699,Predicted intracellular proteins,Evidence at protein level,HPA023274,Uncertain,,Approved,Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 78.0,testis: 34.9,Mixed,,
210,TDRKH,TDRD2,ENSG00000182134,Tudor and KH domain containing,1,151770107-151791416,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA016419, HPA019625",Approved,,Approved,Centrosome<br>Cytosol,Endometrial cancer:1.66e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 76.8;testis: 40.1,cerebral cortex: 13.0,Mixed,,
211,TENM4,"KIAA1302, ODZ4, Ten-M4",ENSG00000149256,Teneurin transmembrane protein 4,11,78652831-79440948,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA019521, HPA065961",Approved,,,,,Mixed,Tissue enhanced,,ovary: 20.8;parathyroid gland: 54.0,thyroid gland: 9.7,Cell line enhanced,,PC-3: 9.9;SH-SY5Y: 18.6
212,THNSL2,"FLJ10916, SOFAT, TSH2",ENSG00000144115,Threonine synthase like 2,2,88170295-88186636,Predicted intracellular proteins,Evidence at protein level,HPA035395,Approved,,,,,Expressed in all,Tissue enhanced,,parathyroid gland: 74.4,thyroid gland: 38.2,Cell line enhanced,,HHSteC: 19.8;T-47d: 21.4
213,TIGD6,DKFZp761E2110,ENSG00000164296,Tigger transposable element derived 6,5,149993118-150001167,Predicted intracellular proteins,Evidence at protein level,HPA044599,Uncertain,,Approved,Nucleoplasm<br>Vesicles<br>Actin filaments,"Colorectal cancer:5.35e-4 (favourable), Pancreatic cancer:5.88e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 21.4,testis: 6.7,Mixed,,
214,TMEM116,FLJ90167,ENSG00000198270,Transmembrane protein 116,12,111931282-112013185,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA040720,Approved,,Approved,Nucleoplasm<br>Microtubules,Renal cancer:1.08e-4 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 57.3,testis: 48.2,Mixed,,
215,TMEM178B,DKFZp547G036,ENSG00000261115,Transmembrane protein 178B,7,141074232-141480380,Predicted membrane proteins,Evidence at protein level,HPA048771,Uncertain,,Uncertain,Nucleoli<br>Vesicles,Renal cancer:4.10e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 19.3;parathyroid gland: 28.9;thyroid gland: 14.4,heart muscle: 7.2,Cell line enhanced,,HAP1: 6.3;RPTEC TERT1: 6.3;SCLC-21H: 7.7;WM-115: 8.9
216,TMEM221,,ENSG00000188051,Transmembrane protein 221,19,17435509-17448567,Predicted membrane proteins,Evidence at protein level,HPA041580,Approved,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 6.8,fallopian tube: 4.2,Cell line enhanced,,AN3-CA: 4.4;PC-3: 6.7;REH: 3.7
217,TMEM61,,ENSG00000143001,Transmembrane protein 61,1,54980792-54992293,Predicted membrane proteins,Evidence at transcript level,HPA030614,Uncertain,,,,"Renal cancer:1.78e-7 (favourable), Colorectal cancer:1.07e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 11.2;salivary gland: 10.1,seminal vesicle: 8.2,Cell line enriched,7.0,RPMI-8226: 16.2
218,TSPEAR,"C21orf29, DFNB98, MGC11251, TSP-EAR",ENSG00000175894,Thrombospondin type laminin G domain and EAR repeats,21,44497892-44711580,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB034203, CAB034204, HPA052995",Approved,,,,,Mixed,Tissue enhanced,,parathyroid gland: 2.7;testis: 2.6,spleen: 1.9,Cell line enhanced,,Karpas-707: 8.0;RPMI-8226: 4.6;SH-SY5Y: 4.0;U-266/70: 4.9;U-266/84: 5.1
219,USP35,KIAA1372,ENSG00000118369,Ubiquitin specific peptidase 35,11,78188812-78214711,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA055213, HPA058592",Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Expressed in all,Tissue enhanced,,parathyroid gland: 34.3,adrenal gland: 14.8,Expressed in all,,
220,VDR,"NR1I1, PPP1R163",ENSG00000111424,"Vitamin D (1,25- dihydroxyvitamin D3) receptor",12,47841537-47943048,"Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters",Evidence at protein level,"CAB004617, HPA047740",,,Enhanced,Nucleoplasm,Renal cancer:4.89e-6 (favourable),Expressed in all,Tissue enhanced,,parathyroid gland: 175.9,small intestine: 57.9,Cell line enhanced,,HDLM-2: 73.7;U-937: 60.2
221,VLDLR,"CARMQ1, CHRMQ1, VLDLRCH",ENSG00000147852,Very low density lipoprotein receptor,9,2621834-2660053,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB032462, HPA051312",Uncertain,,Approved,Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center,Endometrial cancer:5.95e-4 (favourable),Expressed in all,Tissue enhanced,,ovary: 110.0;parathyroid gland: 124.0,fallopian tube: 43.7,Cell line enhanced,,BEWO: 60.5
222,VMO1,,ENSG00000182853,Vitelline membrane outer layer 1 homolog,17,4785285-4786433,Predicted secreted proteins,Evidence at protein level,HPA023038,Uncertain,,,,Renal cancer:1.34e-6 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 34.4,spleen: 14.6,Cell line enhanced,,A549: 2.7;MCF7: 3.0
223,WDR17,,ENSG00000150627,WD repeat domain 17,4,176065834-176182818,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042766, HPA054501",Approved,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,cerebral cortex: 25.2;parathyroid gland: 19.3,thyroid gland: 11.0,Cell line enhanced,,AF22: 7.7;SCLC-21H: 10.5
224,WDR31,FLJ35921,ENSG00000148225,WD repeat domain 31,9,113313222-113340298,Predicted intracellular proteins,Evidence at transcript level,"HPA019340, HPA019347",Approved,,Approved,Nuclear bodies<br>Cytosol,"Renal cancer:1.90e-9 (favourable), Endometrial cancer:1.85e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 16.3,testis: 9.2,Mixed,,
225,WDR86,,ENSG00000187260,WD repeat domain 86,7,151375909-151410727,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 20.9;spleen: 14.3,endometrium: 7.5,Group enriched,5.0,HSkMC: 9.9;NTERA-2: 2.6;SCLC-21H: 6.9;SH-SY5Y: 4.4
226,WNT8B,,ENSG00000075290,Wnt family member 8B,10,100463041-100483744,Predicted secreted proteins,Evidence at transcript level,HPA036570,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.1;parathyroid gland: 1.5;testis: 1.2,kidney: 0.6,Cell line enhanced,,AF22: 2.3;SCLC-21H: 1.3
227,WNT9B,"WNT14B, WNT15",ENSG00000158955,Wnt family member 9B,17,46833201-46886730,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA058361, HPA059572",Approved,,,,,Not detected,Tissue enhanced,,parathyroid gland: 3.1;seminal vesicle: 9.4,skin: 1.4,Not detected,,
228,ZBED6CL,C7orf29,ENSG00000188707,ZBED6 C-terminal like,7,150329789-150332721,Predicted intracellular proteins,Evidence at transcript level,"HPA019724, HPA055805",Approved,,Approved,Nuclear membrane<br>Vesicles,"Renal cancer:1.38e-5 (unfavourable), Pancreatic cancer:2.44e-5 (favourable), Glioma:5.65e-5 (unfavourable), Breast cancer:9.48e-5 (favourable)",Expressed in all,Tissue enhanced,,adrenal gland: 31.7;parathyroid gland: 30.4,lymph node: 9.8,Cell line enhanced,,HDLM-2: 80.9;K-562: 33.8
229,ZBTB22,"BING1, fru, fruitless, ZBTB22A, ZNF297, ZNF297A",ENSG00000236104,Zinc finger and BTB domain containing 22,6,33314406-33317942,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA043848,,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,parathyroid gland: 28.9,epididymis: 11.8,Mixed,,
230,ZFHX3,"ATBF1, ZNF927",ENSG00000140836,Zinc finger homeobox 3,16,72782885-73059698,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059353,Uncertain,,,,"Renal cancer:1.37e-5 (favourable), Breast cancer:1.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 28.3,thyroid gland: 12.4,Mixed,,
231,ZMYND15,DKFZp434N127,ENSG00000141497,Zinc finger MYND-type containing 15,17,4740015-4746119,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA023286,,,Uncertain,Nuclear speckles<br>Cytosol,,Expressed in all,Tissue enhanced,,parathyroid gland: 15.7;testis: 29.5,lung: 7.5,Cell line enhanced,,A-431: 1.9;CAPAN-2: 1.8
232,ZNF229,,ENSG00000278318,Zinc finger protein 229,19,44417519-44448578,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA001494,Uncertain,,Approved,Vesicles<br>Plasma membrane,Renal cancer:8.43e-5 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 6.7,"fallopian tube,thyroid gland: 3.1",Mixed,,
233,ZNF676,,ENSG00000196109,Zinc finger protein 676,19,22179091-22196951,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,parathyroid gland: 4.4;testis: 4.0,thyroid gland: 3.0,Cell line enriched,9.0,NTERA-2: 7.0
234,ZNF69,Cos5,ENSG00000198429,Zinc finger protein 69,19,11887784-11914329,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047845,Uncertain,,Uncertain,Nucleus,Endometrial cancer:1.55e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 24.9,kidney: 10.3,Cell line enhanced,,AF22: 13.8
235,ZNF90,HTF9,ENSG00000213988,Zinc finger protein 90,19,20077994-20127076,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003227,Uncertain,,Approved,Nucleus<br>Golgi apparatus,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 7.6,thyroid gland: 2.7,Cell line enhanced,,AN3-CA: 9.0;NTERA-2: 16.5
